3SBio Inc. Announces Results of 2011 Annual General Meeting

SHENYANG, China, Sept. 21, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the results of shareholder votes at its Annual General Meeting of shareholders held on September 20, 2011.

At the meeting, the Company's shareholders re-elected Mr. Lawrence S. Wizel and Mr. Mingde Yu to serve as members of the Board of Directors, until the expiration of their term.

The Company's shareholders also ratified the appointment of Ernst & Young Hua Ming to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2011.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 700 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information

Investor Contacts


Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820
[email protected]


Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
[email protected]



SOURCE 3SBio Inc.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.